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Introduction: Cystic fibrosis is the most common autosomal recessive genetic disease in the Caucasian population.
Extending knowledge about the molecular pathology on the one hand allows better delineation of the mutations
in the CFTR gene and the other to dramatically increase the predictive power of molecular testing.
Methods: This study reports the results of a molecular screening of cystic fibrosis using DNA samples of patients
enrolled from January 2009 to December 2013. Patients were referred to our laboratory for cystic fibrosis screening
for infertile couples. In addition, we identified the gene mutations present in 76 patients affected by cystic fibrosis
in the pediatric population of Basilicata.
Results: In the 964 infertile couples examined, 132 subjects (69 women and 63 men) resulted heterozygous for one
of the CFTR mutations, with a recurrence of carriers of 6.85%. The recurrence of carriers in infertile couples is
significantly higher from the hypothetical value of the general population (4%).
Conclusions: This study shows that in the Basilicata region of Italy the CFTR phenotype is caused by a small
number of mutations.
Our aim is to develop a kit able to detect not less than 96% of CTFR gene mutations so that the relative risk for
screened couples is superimposable with respect to the general population.
Keywords: Cystic fibrosis, Cystic fibrosis conductance transmembrane regulator, Screening in infertile couples,
Mutation analysis, Polymerase Chain ReactionIntroduction
Cystic fibrosis (CF) is the most common autosomal reces-
sive genetic disease for the Caucasian (white) population.
In Italy, the disease occurs in 1/2500 to 1/3000 Caucasian
newborns, with a carrier incidence ranging from 1/26 to
1/30 in the general population [1,2].
CF is a complex multisystem disease related to the
buildup of thick, sticky mucus that can damage many of
the body's organs (epithelia of the respiratory tract,* Correspondence: domenicodelledera68@gmail.com
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unless otherwise stated.exocrine pancreas, intestine, male genital tract, hepato-
biliary system, and exocrine sweat glands). The pulmon-
ary disease is present in 90% of patients and it is the
major cause of morbidity and mortality in CF.
The CFTR gene provides instructions for making a
glycoprotein called cystic fibrosis transmembrane con-
ductance regulator (1,480 amino acid residues). This
protein works as a channel across the membrane of cells
producing mucus, sweat, saliva, tears, and digestive en-
zymes. The channel negatively transports charged parti-
cles called chloride ions into and out of the cells. The
transport of chloride ions helps control the movement
of water in tissues, which is necessary for the productionral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Number of subjects tested who were carriers of
the cystic fibrosis transmembrane regulator gene
Mutation Men Women Total
G551D 1 2 3
R553X 0 1 1
F508del 35 32 67
N1303K 7 8 15
I148T 4 9 13
G542X 3 6 9
DI507 2 0 2
L1077P 0 2 2
D1152H 1 6 7
W1282X 2 0 2
2183 AA>G 3 0 3
1259insA 0 1 1
4016insT 1 0 1
I507del 1 0 1
2789+5G>A 1 0 1
4382delA 0 2 2
G1244E 1 0 1
621+3A>G 1 0 1
Total 63 69 132
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stance that lubricates and protects the lining of the air-
ways, digestive system, reproductive system and other
organs and tissues [3]. In particular, more than 95% of
men with CF are infertile as a result of azoospermia
caused by congenital bilateral agenesis of the vas deferens
(CBAVD); it occurs in men without pulmonary or gastro-
intestinal manifestations of CF.
Cystic fibrosis is caused by mutations in the CFTR
gene (cystic fibrosis transmembrane regulator), detected
for the first time in 1989. The CFTR gene is located on
the long (q) arm of chromosome 7 (7q31.2) [4,5].
More than 1800 mutations in the CFTR gene have
been identified [6]; many of which are so rare as to be
called ‘private’ as they are only present within individual
families. Moreover, the CFTR mutation detection rate
varies by test method and ethnic background. The most
common mutation, called F508del, is a deletion of one
amino acid at position 508 in the CFTR protein. The
resulting abnormal channel breaks down shortly after it
is made, so it never reaches the cell membrane to trans-
port chloride ions. The F508del mutation, accounts for
two-thirds of all cystic fibrosis alleles worldwide. This
mutation is particularly frequent in people of northern
European ancestry (70% in Anglo-Saxon countries and
50% in the Mediterranean area).
The phenotypic variability is determined by the het-
erogeneity of mutations in the CFTR gene, but also by
many other factors, such as modifier genes, epigenetic
regulation, environment and timeliness in therapy [7,8].
Carrier screening for cystic fibrosis involves analysis for
common mutations in the CFTR gene from people with
no personal history, or family history, of the disease.
This analysis shows whether a person is a carrier, at risk
(one in four) of having a baby with cystic fibrosis if their
partner is also a carrier. Carrier screening has been recom-
mended by the American College of Medical Genetics and
American College of Obstetricians and Gynecologists
(ACMG/ACOG) [9] and the Human Genetics Society of
Australasia (HGSA) [10] and has been established in the
USA, Australia, and parts of Europe [11]. Accurate identi-
fication of CF mutations results in more applicable pro-
grams for prevention, diagnosis, and treatment of CF. In a
study carried out in some areas of Northern Italy, carrier
screening was associated with a decrease in the incidence
of CF [12].
Previous reports about CF patients born in the Basilicata
region (southern Italy) have identified types and incidence
of the most common mutations of the CFTR gene [13,14].
In this study are reported the results of a molecular
screening of CF in patients enrolled from January 2009 to
October 2013 using DNA samples. Patients were referred
to our laboratory for CF screening for infertile couples
[15]. In addition, we identified the gene mutations presentin patients affected by cystic fibrosis in the pediatric popu-
lation of Basilicata.
In this way the incidence and typology of CFTR muta-
tions in Basilicata were characterized and related to pre-
vious reports on CF patients born in the same area.
Results
In the 964 infertile couples examined, 132 subjects (69
women and 63 men) were heterozygous for one of the
mutations of CFTR, with a carrier occurrence of 6.85%
(Table 1). The carrier occurrence in infertile couples is sig-
nificantly higher than the hypothetical value of the general
population (4%). The statistical analysis was performed ac-
cording to the ‘hypothesis test for a proportion’. Our data
indicated an expectation of 6.85% with a sample of 1,928
subjects. The Z-test revealed a value of 6.38% with a P
value <0.0001. Nevertheless, mutation I148T, at first clas-
sified as a mutation, now is considered an ‘innocent’ poly-
morphism, able to be pathogenetic only if present in the
same gene (on the same chromosome) with another poly-
morphism (3199del6). Hence it is necessary, in presence
of polymorphism I148T, to detect the presence of poly-
morphism 3199del6. The polymorphism 3199del6 was not
detected in all patients with the I148T variant.
Among the infertile couples, three men, two of whom
were brothers, were azoospermic with CBAVD. The mo-
lecular analysis of the CFTR gene revealed that the two
Figure 1 76 patients with cystic fibrosis and positive sweat test, all have two genes mutated. SNPs: Single nucleotide polymorphism.
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Table 2 Comparison between the results obtained in this
study and those obtained in a previous study
Castaldo et al. [14] Mutations observed in
the present study
F508del 55.8% (29) 48.62% (141)
N1303K 3.8% (2) 9.31% (27)
G542X 3.8% (2) 8.96% (26)
W1282X 3.8% (2) 1.03% (3)
2183AA>G 5.8% (3) 2.76% (8)
R1162X 0 0
1717-1G>A 1.9% (1) 0
T338I 0 0
R347P 0 0.69% (2)
711+5G>A 0 0
852del22 5.8% (3) 1.03% (3)
4382delA 0 0.69% (2)
1259insA 0 0.34% (1)
4016insT 0 0.34% (1)
R553X 0 0.34% (1)
R1158X 0 0
L1077P 0 1.03% (3)
I502T 0 0
3849+10kbC>T 1.9% (1) 0.34% (1)
D579G 0 0.69% (2)
G1244E 3.8% (2) 0
G1349D 0 0.34% (1)







D1152H 0 3.10% (9)
I148T-3195del6 0 0
I148T (alone) 0 4.48% (13)
R334W 0 0




L558S 1.9% (1) 0.34% (1)
W1063X 0 0
D110H 0 0
S549R (A>C) 1.9% (1) 0.69% (2)
2184insA 0 0
3131del22 0 0
Table 2 Comparison between the results obtained in this




Y849X 1.9% (1) 0.34% (1)
G551D 0 1.03% (3)
621+3A>G 0 0.34% (1)
E831X 0 0
I507del 0 0.69% (2)
IVS8 TG12/t5 0 1.03% (3)
H139R (A->G) 0 0.34% (1)
1248+1G>A 0 0.34% (1)
R74W;V201M;D1270N 0 0.69% (2)
S1455X 0 0.34% (1)
dele 2,3 (21kb) 0 0.34% (1)
991del5 0 0.34% (1)
UNKNOWN 7 %(4) 4.83% (14)
F508C 0 0.69% (2)
TOTAL 52 290
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http://www.jmedicalcasereports.com/content/8/1/339brothers, aged 26 and 29 years old respectively, were
both ‘compound heterozygotes G542X/D1152H’, while
the third one, aged 37 years old, was ‘compound hetero-
zygotes G542X/E831X’.
With regard to the 76 patients with cystic fibrosis and
a positive sweat test, all have two CFTR-mutated genes
(Figure 1).
Discussion
The aim of this study was to characterize, at molecular
level, the most common CFTR mutations in the popula-
tion of the Basilicata region. We have defined the type and
frequency of mutations found and put them in compari-
son with data from previous studies (Table 2) [13,14]. In
this study, we detected mutations that had not been re-
vealed in the two previous studies [13,14]. In infertile cou-
ples from Basilicata, the occurrence of CF carriers is
significantly higher than in the general population (6.85%
vs. 4%). It was not clear if a screening for the general
population would be viable or effective, so we invited the
carriers in the families of affected people to participate in
the research.
In CF, contrary to other genetic diseases (for example
beta thalassemia), the identification of carriers is possible
only through molecular research of CFTR mutations. A
recent report has shown the costs of managing CF for
the Italian National Health System [16]. The results re-
ports a high cost for the chronic and evolutive aspects of
the disease. As mentioned before, molecular screening
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tional Institutes of Health Consensus Development
Conference Statement on genetic testing for cystic fi-
brosis [17]. The target of the screening could be men
and women of reproductive age in the periconceptional
period. A European consensus conference in 2009 has
concluded that for complete information for couples,
each national health system could implement a screen-
ing program. In Italy, the region of Veneto started a
complete screening program for the general population
some years ago. The results have shown a significant
reduction of the incidence of the disease. More re-
cently, an experimental periconceptional program of
CF and thalassemia screening allowed for the identifi-
cation of 94% of CFTR gene mutations, with respect to
80% in the rest of Italy. Moreover, this screening pro-
gram involved a high number of couples [18].
The success of a genetic screening program is
mainly the outcome of educational support informing
the population about the disease, thereby offering the
opportunity to make an informed decision about
reproduction.
In this study, the aim was to establish the a priori risk
of CF carrier status in the Basilicata population and to
offer a reliable screening test to couples planning a preg-
nancy, allowing them to make informed decisions.
Conclusions
This study shows that, in the Basilicata region (Italy), it
was observed that the CFTR phenotype is caused by a
small number of mutations.
The knowledge of the frequency of mutations preva-
lent in CFTR genes in the province of Matera allows de-
velopment of kits for their detection.
Our aim is to develop a kit able to detect not less than
96% of CTFR gene mutations so that the relative risk for
the couples screened is superimposable with respect to
the general population.Table 3 List of 60 mutations in the cystic fibrosis transmembra
F508del I507del F508C 621
I502T 1706del17 1677delTA R11
G542X 1717-1G>A Q552X 852
G551D S549R(A>C) 2183AA>G T33
N1303K 4016insT 3849+10kb C>T R34
G85E 711+5G>A 711+1G>T 125
2789+5G>A W1282X G1244E R10
I148T 3199del6 S912X R11
R1162X 4382delA D1152H L10
L1065P R553X PoliT: 5T, 7T, 9TExtending knowledge about the molecular path-
ology, on the one hand, allows better delineation of
the mutations in the CFTR gene, and on the other,
dramatically increases the predictive power of molecu-
lar testing.
Methods
In this study, we investigated 964 infertile couples (1.928
subjects examined; 3.856 alleles studied) born and living
in Basilicata, from 2009 to December 2013 (five years).
Moreover, we evaluated gene mutation of CFTR in 76 chil-
dren born in Basilicata (152 CF alleles examined) with a
positive sweat test (>60mmol/L). Written informed consent
was obtained from the subjects examined for publication of
this study in compliance with the Helsinki Declaration.
We applied the following tests to each patient after a
venous blood sample was collected (in EDTA-K3).
Molecular analysis of the CFTR gene was performed
following these steps:
– DNA isolation, starting from 25μl of blood, using
the Promega extraction kit (DNA IQ™ System, cod.
C6701; Promega Italy S.r.l., Milan, Italy).
– Polymerase chain reaction (PCR) and reverse
hybridization. The procedure includes two steps:
PCR amplification using biotinylated primers and
hybridization of amplification products to a test
strip containing allele-specific oligonucleotide probes
immobilized as an array of parallel lines. Bound
biotinylated sequences are detected using
streptavidin-alkaline phosphatase and color substrates.
The amplification and the reverse hybridization on a
strip were obtained with the use of commercial kits
produced by Nuclear Laser Medicine S.r.l., Settala
(MI), Italy (cod. AC023/AC025 and AC089): genetic
tests aimed at checking 60 mutations in the CFTR
genes. The mutations analyzed are listed in Table 3.
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Table 4 Sequence of oligonucleotides for each exon, with
the annealing temperatures (T°A) and the length in base
pair (bp) of the amplified product
Exon Sequence of primers T°A bp
1 GAGAAAGCCGCTAGAGCAAA(CF1F) 55°C 394
TCCTTTACCCCAAACCCAAC(CF1R)
2 TCCAAATCTGTATGGAGACCA(CF2F) 55°C 603
TCAGTGTGAAAATGAGATGTTCC(CF2R)
3 TCTGGCTGAGTGTTTGGTGT(CF3F) 55°C 399
TTTGGAGTTGGATTCATCCTTT(CF3R)
4 AAACTTGTCTCCCACTGTTGC(CF4F) 55°C 453
GGCCTGTGCAAGGAAGTATT(CF4R)
5 GTGCCTAGATGCTGGGAAAT(CF5F) 55°C 393
AAAACTCCGCCTTTCCAGTT(CF5R)
6a TGCTATGTGCTCCATGTAATGA(CF6AF) 55°C 415
TGCATAGAGCAGTCCTGGTT(CF6AR)
6b TGCCCATCTGTTGAATAAAAG(CF6BF) 55°C 411
CCCATGAAAGTGAATTTGTGC(CF6BR)
7 TTCCATTCCAAGATCCCTGA(CF7F) 55°C 404
GCACATTTTTGCAAAGTTCA(CF7F)
8 GAATCCTAGTGCTTGGCAAAT(CF8F) 55°C 404
GATCCTCCTTCCAGTTCTACCA(CF8R)
9 GGCCATGTGCTTTTCAAACT(CF9F) 55°C 389
CTCCAAAAATACCTTCCAGCA(CF9R)
10 TGAATCCTGAGCGTGATTTG(CF10F) 55°C 435
TTCATGTGTTTGCAAGCTTCTT(CF10R)
11 GAAGGAAGATGTGCCTTTCAA(CF11F) 55°C 395
CCAAGATACGGGCACAGATT(CF11R)
12 TCAGTGAATCGATGTGGTGAC(CF12F) 55°C 419
ATGAGGCGGTGAGAAAAGGT(CF12R)
13-1 TCATGCTATCAGAATTCACAAGG(CF13F1) 56°C 575
GGGAGTCTTTTGCACAATGG(CF13R1)
13-2 CTGGAGAGTTTGGGGAAAAA(CF13F2) 56°C 449
AAATACCCCCAAGCGATGTA(CF13R2)
14a CAATGGTGGCATGAACTGT(CF14AF) 55°C 437
GTGGTTCTACTTGTTGATTTTTCAG(CF14AR)
14b TGGCTTTCTTGTGAGGTTCA(CF4BF) 55°C 446
TGCTTGGGAGAAATGAAACA(CF14BR)
15 GTCGCCAAATAACGATTTCC(CF15F) 55°C 406
AGGTTCAACAAAGGGCACAT(CF15R)
16 TTTGGGTTCTGAATGCGTCT(CF16F) 55°C 388
GGCCAGGTAAGCAGTTCTGA(CF16R)
17a CTCACCAACATGTTTTCTTTGA(CF17AF) 55°C 399
CCAAAATGAAGTCACATGGTCA(CF17AR)
17b GAATGGCACCAGTGTGAAAA(CF17BF) 55°C 682
CAATCTGTGTGCATCGGTTT(CF17BR)
Table 4 Sequence of oligonucleotides for each exon, with
the annealing temperatures (T°A) and the length in base
pair (bp) of the amplified product (Continued)
18 TGTGCCCTAGGAGAAGTGTG(CF18F) 55°C 335
TGACAGATACACAGTGACCCTCA(CF18R)
19 GCCCGACAAATAACCAAGTG(CF19F) 55°C 399
GCAAGCAGTGTTCAAATCTCA(CF19R)
20 CCAATTCCTTATGCCCAGTT(CF20F) 55°C 408
TGGCTAAGTCCTTTTGCTCA(CF20R)
21 TGATGGTAAGTACATGGGTGTTTC(CF21F) 57°C 578
GGAGCCATACCAGTGAGGAG(CF21R)
22 TCAAATGGTGGCAGGTAGTG(CF22F) 55°C 382
TCACCATGAAGCAGGCATAA(CF22R)
23 CCCATGGTTGAAAAGCTGAT(CF23F) 55°C 417
TGAGTAAAGCTGGATGGCTG(CF23R)
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CTFR gene, with reverse dot blot, it is possible to
detect 90% of the most common CF alleles in Southern
Italy (the regions of Campania, Puglia, Basilicata and
Molise).
– The patients who tested negative or with a single
mutation detected by reverse dot blot and with a
clinical suspicion of atypical cystic fibrosis were
analyzed with a complete scanning of the codificant
region, through amplification and direct sequencing of
27 exones of the CFTR gene. In patients negative for
reverse dot blot and in whom there were no clinical
signs of cystic fibrosis, sequencing of the CFTR gene
was not necessary. DNA sequencing is not essential,
since the detection of innocent polymorphisms is not
important to control the disease. The sequence of
oligonucleotides for each exone, with the annealing
temperatures (T°A) and the length in base pair (bp) of
the amplified product, are reported in Table 4. The
amplification conditions for the 27 exones change
according to the annealing temperature (T°A.), which
depends on the oligonucleotides used, which in turn
are specific for analysis of each exone. The
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